{
    "clinical_study": {
        "@rank": "95689", 
        "arm_group": [
            {
                "arm_group_label": "moxifloxacin Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment at uPID with moxifloxacin"
            }, 
            {
                "arm_group_label": "Ofloxacin Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment at uPID with Ofloxacin plus metronidazole"
            }
        ], 
        "brief_summary": {
            "textblock": "We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg\n      twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin\n      monotherapy, 400 mg once daily, for 14 days"
        }, 
        "brief_title": "Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pelvic Inflammatory Disease", 
        "condition_browse": {
            "mesh_term": [
                "Pelvic Inflammatory Disease", 
                "Pelvic Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women diagnosed uncomplicated PID\n\n          2. Patients age are between 14 with 45\n\n          3. Pelvic tenderness and vaginal discharge\n\n        Exclusion Criteria:\n\n          1. Urinary Tract Enfections\n\n          2. Tubo-ovarian abscess and complicated PID\n\n          3. H\u0131story of antibiotics treatment\n\n          4. Other pelvic pain causes\n\n          5. Endometriosis\n\n          6. Delivery,abortion and surgery within last months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "1303", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01799356", 
            "org_study_id": "Asicioglu03", 
            "secondary_id": [
                "treatment", 
                "treatment uPID"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "moxifloxacin Group", 
                "description": "daily 400 mg moksifloksasin", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug", 
                "other_name": "new generetaion flouroquinolon antibiotics"
            }, 
            {
                "arm_group_label": "Ofloxacin Group", 
                "description": "daily 800 mg oflaksasin plus 1000 mg metronidazol treatment", 
                "intervention_name": "Ofloxacin", 
                "intervention_type": "Drug", 
                "other_name": "floroquinolon antibiotics"
            }, 
            {
                "arm_group_label": "Ofloxacin Group", 
                "description": "daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID", 
                "intervention_name": "Metronidazole", 
                "intervention_type": "Drug", 
                "other_name": "anaerobic antibiotics"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Ofloxacin", 
                "Antibiotics, Antitubercular", 
                "Metronidazole", 
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Treatment, moksifloksasin", 
        "lastchanged_date": "August 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Samatya", 
                        "country": "Turkey", 
                        "state": "Fatih", 
                        "zip": "34180"
                    }, 
                    "name": "T.C.S.B. \u0130stanbul Training Research Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u0130stanbul", 
                        "country": "Turkey", 
                        "state": "Kucukcekmece", 
                        "zip": "34280"
                    }, 
                    "name": "T.C.S.B. Kanuni Sultan Suleyman Training Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mardin", 
                        "country": "Turkey", 
                        "zip": "47000"
                    }, 
                    "name": "T.C.S.B Mardin Women and Children Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u015ei\u015fli", 
                        "country": "Turkey", 
                        "zip": "34150"
                    }, 
                    "name": "T.C.S.B. \u015ei\u015fli Etfal Training Research Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "T.C.S.B. Kan\u0131ni Sultan Suleyman Training Hospital", 
            "last_name": "Kemal Gungorduk, md", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Turkey: Ethics Committee"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Clinically cure", 
            "safety_issue": "Yes", 
            "time_frame": "21 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01799356"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istanbul Bakirkoy Maternity and Children Diseases Hospital", 
            "investigator_full_name": "Osman A\u015f\u0131c\u0131o\u011flu", 
            "investigator_title": "Istanbul Sisli Etfal Training Research Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Microbiological cure", 
            "safety_issue": "Yes", 
            "time_frame": "21 Days"
        }, 
        "source": "Istanbul Bakirkoy Maternity and Children Diseases Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istanbul Bakirkoy Maternity and Children Diseases Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}